Posted by Michael Wonder on 26 Dec 2021
Investigational Alzheimer’s disease therapy lecanemab granted FDA fast track designation
23 December 2021 - Eisai and Biogen announced today that lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of early Alzheimer’s disease, was granted fast track designation by the U.S. FDA.
FDA granted breakthrough therapy designation for lecanemab in June of 2021.
